(NASDAQ: MIST) Milestone Pharmaceuticals's forecast annual revenue growth rate of 243.08% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.24%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.13%.
Milestone Pharmaceuticals's revenue in 2026 is $2,343,000.On average, 9 Wall Street analysts forecast MIST's revenue for 2026 to be $489,775,053, with the lowest MIST revenue forecast at $341,622,457, and the highest MIST revenue forecast at $784,337,274. On average, 9 Wall Street analysts forecast MIST's revenue for 2027 to be $3,047,088,061, with the lowest MIST revenue forecast at $1,903,325,118, and the highest MIST revenue forecast at $4,523,011,613.
In 2028, MIST is forecast to generate $13,367,348,113 in revenue, with the lowest revenue forecast at $4,404,489,536 and the highest revenue forecast at $37,412,887,970.